Compare Rockwell Automation (ROK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs TransMedics Group Inc — how do they compare? Rockwell Automation trades at $425.63 (market cap $47.32B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: Rockwell Automation is far larger — about 15.8× TransMedics Group Inc's market cap, and Rockwell Automation pays a 1.3% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ROK | TMDX | |
|---|---|---|
Market Cap | $47.32B | $3.00B |
Sector | Industrials | Technology |
52-Week High | $495.08 | $150.42 |
52-Week Low | $333.75 | $61.99 |
Enterprise Value | $50.45B | $3.39B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and mixed sentiment. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.49 exceeding expectations, but faces declining profit margins from 14.1% in 2023 to 10.41% in 2025. Analyst consensus is a Buy with a $514 price target, though technical indicators show resistance near $434 and support at $427.
The stock offers upside based on analyst targets and robust cash flow, but risks include margin pressure, high valuation multiples, and macroeconomic sensitivity. Institutional interest remains positive with recent investments, but investors should weigh the bearish technical trend against fundamental strengths in industrial automation demand.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
